NCT01493726View on ClinicalTrials.gov

A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Schizophrenia
Interventions
DRUG

ALKS 9072, Low dose

IM injection, given monthly

DRUG

ALKS 9072, Med dose

IM injection, given monthly

DRUG

ALKS 9072, High dose

IM injection, given monthly

DRUG

Placebo

Dosed matched placebo IM injection, given monthly

Trial Locations (6)

19139

Alkermes Investigational Site, Philadelphia

30338

Alkermes Investigational Site, Atlanta

60169

Alkermes Investigational Site, Hoffman Estates

63118

Alkermes Investigational Site, St Louis

70562

Alkermes Investigational Site, Irving

08046

Alkermes Investigational Site, Willingboro

Sponsors

Lead Sponsor

Alkermes, Inc.
All Listed Sponsors
lead

Alkermes, Inc.

INDUSTRY